Literature DB >> 31522990

Risk factors of Clostridium difficile-associated diarrhea in hospitalized adults: Vary by hospitalized duration.

Yuan-Pin Hung1, Jen-Chieh Lee2, Bo-Yang Tsai3, Jia-Ling Wu2, Hsiao-Chieh Liu4, Hsiu-Chuan Liu5, Hsiao-Ju Lin1, Pei-Jane Tsai6, Wen-Chien Ko7.   

Abstract

BACKGROUND: Clostridium difficile is the leading cause of nosocomial infectious diarrhea. Hospitalized patients were at risk of C. difficile-associated diarrhea (CDAD). However the risk factors of CDAD in patients with different hospitalization period are not clear.
MATERIAL AND METHODS: A prospective investigation was conducted in medical wards of a district hospital in southern Taiwan, from January 2011 to January 2013. We arbitrary divided patients into two groups: hospitalized for at most 14 days and 15-30 days, and analyzed their risk factors for CDAD.
RESULTS: Overall 451 patients were enrolled. The multivariable analysis of 19 (8.0%) patients developing CDAD within 14 days' hospital stay and 216 patients hospitalized for ≤ 14 days without CDAD showed malignancy (odds ratio [OR] 7.15, 95% confidence interval [CI] 1.82-28.09; P = 0.005), prior cephalosporin (OR 10.8, 95% CI 1.3-93.9; P = 0.03) and proton pump inhibitor (PPI; OR 7.1, 95% CI 2.1-24.7; P = 0.002) therapy were independently related to CDAD (Table 3), but hypertension (OR 0.2, 95% CI 0.1-0.7; P = 0.01) was reversely related to CDAD. However, of 9 (4.2%) patients developing CDAD later (15-30 days' hospital stay) and 207 patients with longer hospitalization (15-30 days) but free of CDAD, malignancy (OR 14.0, 95% CI 1.6-124.9; P = 0.02) and underlying diabetes mellitus (OR 20.5, 95% CI 2.9-144.9; P = 0.002) were independent risk factors of CDAD.
CONCLUSION: Risk factors for CDAD among hospitalized patients varied by the duration of hospital stay. Intervention strategies to prevent CDAD may be different in terms of hospital stay duration.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Cephalosporin; Clostridium difficile; Diabetes mellitus; Malignancy; Prolonged hospitalization; Proton pump inhibitors

Year:  2019        PMID: 31522990     DOI: 10.1016/j.jmii.2019.07.004

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  6 in total

1.  Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.

Authors:  Ching-Chi Lee; Jen-Chieh Lee; Chun-Wei Chiu; Pei-Jane Tsai; Wen-Chien Ko; Yuan-Pin Hung
Journal:  Microbiol Spectr       Date:  2021-10-20

2.  Clostridium butyricum therapy for mild-moderate Clostridioides difficile infection and the impact of diabetes mellitus.

Authors:  Jen-Chieh Lee; Chun-Wei Chiu; Pei-Jane Tsai; Ching-Chi Lee; I-Hsiu Huang; Wen-Chien Ko; Yuan-Pin Hung
Journal:  Biosci Microbiota Food Health       Date:  2021-11-03

3.  Membrane Cholesterol Is Crucial for Clostridium difficile Surface Layer Protein Binding and Triggering Inflammasome Activation.

Authors:  Yu Chen; Kai Huang; Liang-Kuei Chen; Hui-Yu Wu; Chih-Yu Hsu; Yau-Sheng Tsai; Wen-Chien Ko; Pei-Jane Tsai
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

4.  IL-16 and BCA-1 Serum Levels Are Associated with Disease Severity of C. difficile Infection.

Authors:  Dor Gotshal; Maya Azrad; Zohar Hamo; Orna Nitzan; Avi Peretz
Journal:  Pathogens       Date:  2021-05-20

5.  Effect of Doxycycline in Decreasing the Severity of Clostridioides difficile Infection in Mice.

Authors:  Bo-Yang Tsai; Yi-Hsin Lai; Chun-Wei Chiu; Chih-Yu Hsu; Yi-Hsuan Chen; Yueh-Lin Chen; Pei-Jane Tsai; Yuan-Pin Hung; Wen-Chien Ko
Journal:  Antibiotics (Basel)       Date:  2022-01-17

6.  The Role of Toll-Like Receptor-2 in Clostridioides difficile Infection: Evidence From a Mouse Model and Clinical Patients.

Authors:  Yi-Hsin Lai; Bo-Yang Tsai; Chih-Yu Hsu; Yi-Hsuan Chen; Po-Han Chou; Yueh-Lin Chen; Hsiao-Chieh Liu; Wen-Chien Ko; Pei-Jane Tsai; Yuan-Pin Hung
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.